Sinovac Biotech Ltd. (SVA) Upgraded to “Hold” by TheStreet
Shares of Sinovac Biotech (NASDAQ:SVA) traded up 0.66% during trading on Monday, reaching $6.14. Sinovac Biotech has a 12-month low of $4.38 and a 12-month high of $7.16. The firm’s market capitalization is $349.58 million. The company’s 50-day moving average price is $6.07 and its 200-day moving average price is $5.95.
Sinovac Biotech (NASDAQ:SVA) last announced its earnings results on Monday, November 28th. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.01. The company had revenue of $28.74 million for the quarter, compared to analyst estimates of $16.76 million. Sinovac Biotech had a negative return on equity of 10.26% and a negative net margin of 17.94%. During the same quarter in the previous year, the company earned ($0.01) earnings per share. On average, equities research analysts forecast that Sinovac Biotech will post ($0.05) EPS for the current year.
Several institutional investors have recently bought and sold shares of SVA. State Street Corp acquired a new position in Sinovac Biotech during the second quarter valued at approximately $100,000. TFS Capital LLC increased its position in Sinovac Biotech by 86.8% in the second quarter. TFS Capital LLC now owns 24,650 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 11,451 shares during the period. OMERS ADMINISTRATION Corp increased its position in Sinovac Biotech by 5.6% in the second quarter. OMERS ADMINISTRATION Corp now owns 35,700 shares of the biopharmaceutical company’s stock valued at $212,000 after buying an additional 1,900 shares during the period. Panagora Asset Management Inc. increased its position in Sinovac Biotech by 4.7% in the second quarter. Panagora Asset Management Inc. now owns 42,816 shares of the biopharmaceutical company’s stock valued at $254,000 after buying an additional 1,929 shares during the period. Finally, GLG Partners LP acquired a new position in Sinovac Biotech during the second quarter valued at approximately $343,000. Institutional investors and hedge funds own 19.92% of the company’s stock.
Sinovac Biotech Company Profile
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.
Receive News & Ratings for Sinovac Biotech Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.